Pre-made Muromonab-Cd3 benchmark antibody (Whole mAb, anti-CD3E therapeutic antibody, Anti-CD3epsilon/IMD18/T3E/TCRE Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Anti-CD3E therapeutic antibody (Pre-made Muromonab-Cd3 biosimilar, Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Muromonab-CD3 (trade name Orthoclone OKT3, marketed by Janssen-Cilag) is an immunosuppressant drug given to reduce acute rejection in patients with organ transplants.[1][2] It is a monoclonal antibody targeted at the CD3 receptor,[3] a membrane protein on the surface of T cells. It was the first monoclonal antibody to be approved for clinical use in humans.[2]
| Products Name (INN Index) | Pre-Made Muromonab-Cd3 3Iosimilar, Whole Mab, Anti-Cd3E Antibody: Anti-CD3epsilon/IMD18/T3E/TCRE therapeutic antibody |
|---|---|
| INN Name | muromonab-CD3 |
| Target | CD3E |
| Format | Whole mAb |
| Derivation | Mus musculus |
| Species Reactivity | Human |
| CH1 Isotype | IgG2a – kappa |
| VD LC | IgG2a – kappa |
| Highest_Clin_Trial (Jan '20) | NA |
| Est. Status | NA |
| 100% SI Structure | NA |
| 99% SI Structure | NA |
| 95-98% SI Structure | NA |
| Year Proposed | NA |
| Year Recommended | NA |
| Companies | Centocor?Ortho Biotech?Products?LP (Raritan NJ USA) / Janssen?Biotech, Inc (Horsham PA USA) |
| Conditions Approved | NA |
| Conditions Active | NA |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | CD3E |
| Package |
